株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の癌バイオマーカー市場の予測

Global Cancer Biomarker Market Forecast 2019-2027

発行 Inkwood Research 商品コード 542499
出版日 ページ情報 英文 132 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
世界の癌バイオマーカー市場の予測 Global Cancer Biomarker Market Forecast 2019-2027
出版日: 2019年01月14日 ページ情報: 英文 132 Pages
概要

当レポートでは、世界の癌バイオマーカー市場について調査分析し、市場概要、セグメント別の市場分析、地域別分析、競合分析など、体系的な情報を提供しています。

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場決定要因

  • 市場促進要因
  • 市場抑制要因
  • 市場の機会
  • 市場の課題

第5章 市場区分

  • 発見・診断別
  • 疾患別

第6章 主要アナリティクス

  • ファイブフォースモデル
  • 機会マトリクス
  • 主な購入基準
  • ベンダー情勢

第7章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 企業プロファイル

  • 競合情勢
  • ABBOTT LABORATORIES
  • AFFYMETRIX, INC.
  • AGENDIA N.V.
  • AGILENT TECHNOLOGIES, INC.
  • ASTELLAS PHARMA INC.
  • BECTON DICKINSON AND COMPANY
  • CLARIENT, INC.
  • DIADEXUS INC.
  • ILLUMINA, INC
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS LTD
  • AMBRILIA BIOPHARMA INC.
  • AUREON BIOSCIENCES, INC
  • BIOMODA INC.
目次
Product Code: 7093

KEY FINDINGS

The global cancer biomarker market is expected to grow at a CAGR of 11.32% between the years 2019-2027. Some of the important drivers for the global cancer biomarker market include encouragement by the FDA for biomarker development, the adoption of western lifestyles in developing countries, heavy investments by government and private funds for cancer-related research, etc.

MARKET INSIGHTS

The global cancer biomarker market is segmented into profiling technology which is divided into omic technology, imaging technologies, immunoassays and cytogenetic-based tests. The market is also segmented into biomarker that includes genetic biomarkers, protein biomarkers and glyco biomarkers. The market by cancer type is bifurcated into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer and others cancer type. The application segment is divided into diagnostics, drug discovery and development, prognostics, risk assessment and others.

REGIONAL INSIGHTS

The global cancer biomarker market is geographically segmented into North America (U.S. & Canada), Asia-Pacific (India, China, Japan, Australia, South Korea, and Rest of APAC), Europe (United Kingdom, Germany, Italy, France, Spain, rest of Europe) and the Rest of World (Latin America, Middle East and North Africa and Rest of Africa). The North American region is the most dominant region in the global market, with the United States acting as the major contributor. Moreover, the Asia-Pacific region is anticipated to be the fastest growing regional market owing to the increasing prevalence of cancer in the region.

COMPETITIVE INSIGHTS

Some of the noted companies in the global market are Abbott Laboratories, Agendia N.V., Agilent Technologies, Inc., Aureon Biosciences, Inc., Astellas Pharma Inc., Beckman Coulter, Becton Dickinson and Company, Bristol-Myers Squibb, Celgene Corporation, Clarient, Inc. (Acquired By Neogenomics Laboratories), Diadexus Inc. (Acquired By Diazyme Laboratories), Illumina, Inc., Roche Diagnostics Ltd, Sanofi and Qiagen N.V.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
    • 3.2.2. GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
    • 3.2.3. BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
    • 3.2.4. DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. ADOPTION OF WESTERN LIFESTYLES IN DEVELOPING REGIONS
    • 4.2.2. GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
    • 4.2.3. ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
    • 4.2.4. IMPROVED PRECISION AND SPEED OF DIAGNOSIS
    • 4.2.5. HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
    • 4.2.6. DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
    • 4.2.7. GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
    • 4.2.8. TECHNOLOGICAL ADVANCEMENTS
    • 4.2.9. GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. POOR COMPENSATION STRUCTURES
    • 4.3.2. LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
    • 4.3.3. TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
    • 4.3.4. HIGH COST OF DRUG DEVELOPMENT
    • 4.3.5. UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
    • 4.4.2. SUPPORTS ON BIOMARKERS TEST
    • 4.4.3. GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
    • 4.4.4. ADVANCEMENT OF CANCER DRUGS RESEARCH
  • 4.5. MARKET CHALLENGES
    • 4.5.1. LACKING ACCEPTANCE OF THE CANCER BIOMARKER
    • 4.5.2. UNFAVORABLE COMPENSATION SITUATION
    • 4.5.3. HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
    • 4.5.4. RIGOROUS REGULATORY AGENDA
    • 4.5.5. DEARTH OF SKILFUL WORKERS

5. MARKET BY PROFILING TECHNOLOGY

  • 5.1. OMIC TECHNOLOGY
    • 5.1.1. GENOMICS
      • 5.1.1.1. NEXT-GENERATION SEQUENCING (NGS)
      • 5.1.1.2. MICROARRAY
      • 5.1.1.3. POLYMERASE CHAIN REACTION (PCR)
    • 5.1.2. PROTEOMICS
      • 5.1.2.1. MASS SPECTROMETRY
      • 5.1.2.2. 2D GEL ELECTROPHORESIS
      • 5.1.2.3. PROTEIN MICROARRAY TECHNOLOGY
      • 5.1.2.4. ANTIBODY ARRAY TECHNOLOGY
      • 5.1.2.5. PEPTIDE ARRAY TECHNOLOGY
    • 5.1.3. OTHER OMIC TECHNOLOGIES
      • 5.1.3.1. METABOLOMICS
      • 5.1.3.2. GLYCOMICS
  • 5.2. IMAGING TECHNOLOGIES
    • 5.2.1. MAGNETIC RESONANCE IMAGING (MRI)
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY (PET)
    • 5.2.3. COMPUTED TOMOGRAPHY
    • 5.2.4. MAMMOGRAPHY
    • 5.2.5. ULTRASOUND
  • 5.3. IMMUNOASSAYS
    • 5.3.1. IMMUNOHISTOCHEMISTRY (IHC) TESTS
    • 5.3.2. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
    • 5.3.3. FLOW CYTOMETRY
  • 5.4. CYTOGENETIC-BASED TESTS
    • 5.4.1. IN SITU HYBRIDIZATION
    • 5.4.2. OTHERS CYTOGENETIC-BASED TESTS

6. MARKET BY BIOMARKER

  • 6.1. GENETIC BIOMARKERS
  • 6.2. PROTEIN BIOMARKERS
  • 6.3. GLYCO BIOMARKERS

7. MARKET BY CANCER TYPE

  • 7.1. LUNG CANCER
  • 7.2. BREAST CANCER
  • 7.3. COLORECTAL CANCER
  • 7.4. PROSTATE CANCER
  • 7.5. STOMACH CANCER
  • 7.6. OTHERS CANCER TYPE

8. MARKET BY APPLICATION

  • 8.1. DIAGNOSTICS
  • 8.2. DRUG DISCOVERY AND DEVELOPMENT
  • 8.3. PROGNOSTICS
  • 8.4. RISK ASSESSMENT
  • 8.5. OTHER APPLICATION

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCE ANALYSIS
    • 9.1.1. THREAT OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE PRODUCT
    • 9.1.3. BARGAINING POWER OF BUYER
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
    • 9.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 9.2. KEY BUYING CRITERIA
    • 9.2.1. PRICING
    • 9.2.2. EFFICACY
    • 9.2.3. APPLICATION AND EFFECTIVENESS
  • 9.3. PATENT ANALYSIS
  • 9.4. ONCOLOGY DRUGS APPROVALS BY THE FDA
  • 9.5. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. THE UNITED STATES
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. GERMANY
    • 10.2.2. THE UNITED KINGDOM
    • 10.2.3. FRANCE
    • 10.2.4. ITALY
    • 10.2.5. SPAIN
    • 10.2.6. REST OF EUROPE
  • 10.3. ASIA PACIFIC
    • 10.3.1. CHINA
    • 10.3.2. INDIA
    • 10.3.3. JAPAN
    • 10.3.4. SOUTH KOREA
    • 10.3.5. AUSTRALIA
    • 10.3.6. REST OF APAC
  • 10.4. REST OF WORLD
    • 10.4.1. LATIN AMERICA
    • 10.4.2. MIDDLE EAST AND AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET SHARE ANALYSIS
  • 11.2. COMPANY PROFILES
    • 11.2.1. ABBOTT LABORATORIES
      • 11.2.1.1. COMPANY OVERVIEW
      • 11.2.1.2. PRODUCT PORTFOLIO
      • 11.2.1.3. SCOT ANALYSIS
      • 11.2.1.4. STRATEGIC INITIATIVES
    • 11.2.2. AGENDIA N.V.
      • 11.2.2.1. COMPANY OVERVIEW
      • 11.2.2.2. PRODUCT PORTFOLIO
      • 11.2.2.3. SCOT ANALYSIS
      • 11.2.2.4. STRATEGIC INITIATIVES
    • 11.2.3. AGILENT TECHNOLOGIES, INC.
      • 11.2.3.1. COMPANY OVERVIEW
      • 11.2.3.2. PRODUCT PORTFOLIO
      • 11.2.3.3. SCOT ANALYSIS
      • 11.2.3.4. STRATEGIC INITIATIVES
    • 11.2.4. AUREON BIOSCIENCES, INC
      • 11.2.4.1. COMPANY OVERVIEW
      • 11.2.4.2. PRODUCT PORTFOLIO
      • 11.2.4.3. SCOT ANALYSIS
      • 11.2.4.4. STRATEGIC INITIATIVES
    • 11.2.5. ASTELLAS PHARMA INC.
      • 11.2.5.1. COMPANY OVERVIEW
      • 11.2.5.2. PRODUCT PORTFOLIO
      • 11.2.5.3. SCOT ANALYSIS
      • 11.2.5.4. STRATEGIC INITIATIVES
    • 11.2.6. BECKMAN COULTER
      • 11.2.6.1. COMPANY OVERVIEW
      • 11.2.6.2. PRODUCT PORTFOLIO
      • 11.2.6.3. SCOT ANALYSIS
      • 11.2.6.4. STRATEGIC INITIATIVES
    • 11.2.7. BECTON DICKINSON AND COMPANY
      • 11.2.7.1. COMPANY OVERVIEW
      • 11.2.7.2. PRODUCT PORTFOLIO
      • 11.2.7.3. SCOT ANALYSIS
      • 11.2.7.4. STRATEGIC INITIATIVES
    • 11.2.8. BRISTOL-MYERS SQUIBB
      • 11.2.8.1. COMPANY PROFILES
      • 11.2.8.2. PRODUCT PORTFOLIO
      • 11.2.8.3. SCOT ANALYSIS
      • 11.2.8.4. STRATEGIC INITIATIVES
    • 11.2.9. CELGENE CORPORATION
      • 11.2.9.1. COMPANY OVERVIEW
      • 11.2.9.2. PRODUCT PORTFOLIO
      • 11.2.9.3. SCOT ANALYSIS
      • 11.2.9.4. STRATEGIC INITIATIVES
    • 11.2.10. CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
      • 11.2.10.1. COMPANY OVERVIEW
      • 11.2.10.2. PRODUCT PORTFOLIO
      • 11.2.10.3. SCOT ANALYSIS
      • 11.2.10.4. STRATEGIC INITIATIVES
    • 11.2.11. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
      • 11.2.11.1. COMPANY OVERVIEW
      • 11.2.11.2. PRODUCT PORTFOLIO
      • 11.2.11.3. SCOT ANALYSIS
      • 11.2.11.4. STRATEGIC INITIATIVES
    • 11.2.12. ILLUMINA, INC.
      • 11.2.12.1. COMPANY OVERVIEW
      • 11.2.12.2. PRODUCT PORTFOLIO
      • 11.2.12.3. SCOT ANALYSIS
      • 11.2.12.4. STRATEGIC INITIATIVES
    • 11.2.13. ROCHE DIAGNOSTICS LTD
      • 11.2.13.1. COMPANY OVERVIEW
      • 11.2.13.2. PRODUCT PORTFOLIO
      • 11.2.13.3. SCOT ANALYSIS
      • 11.2.13.4. STRATEGIC INITIATIVES
    • 11.2.14. SANOFI
      • 11.2.14.1. COMPANY OVERVIEW
      • 11.2.14.2. PRODUCTS PORTFOLIO
      • 11.2.14.3. SWOT ANALYSIS
      • 11.2.14.4. STRATEGIC INITIATIVES
    • 11.2.15. QIAGEN N.V.
      • 11.2.15.1. COMPANY OVERVIEW
      • 11.2.15.2. PRODUCT PORTFOLIO
      • 11.2.15.3. SCOT ANALYSIS
      • 11.2.15.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 2 RECENT RESEARCH ON BIOMARKERS
  • TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS
  • TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
  • TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR
  • TABLE 6 GLOBAL CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL OMIC TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL OMIC TECHNOLOGY MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL GENOMICS MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL PROTEOMICS MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL IMAGING TECHNOLOGIES MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL IMAGING TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL IMMUNOASSAYS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL IMMUNOASSAYS MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY TYPE 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
  • TABLE 19 GLOBAL GENETIC BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 20 GLOBAL PROTEIN BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 21 GLOBAL GLYCO BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 22 GLOBAL CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
  • TABLE 23 GLOBAL LUNG CANCER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 24 GLOBAL BREAST CANCER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 25 GLOBAL COLORECTAL CANCER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 26 GLOBAL PROSTATE CANCER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 27 GLOBAL STOMACH CANCER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 28 GLOBAL OTHERS CANCER TYPE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 29 GLOBAL CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 30 GLOBAL DIAGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 31 GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 32 GLOBAL PROGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 33 GLOBAL RISK ASSESSMENT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 34 GLOBAL OTHER APPLICATION MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 35 PATENT PRODUCTS WITH THE EXPIRY DATE
  • TABLE 36 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
  • TABLE 37 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
  • TABLE 38 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
  • TABLE 39 GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 40 NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 41 EUROPE CANCER BIOMARKER MARKET BY COUNTRY 2018-2026 ($ MILLION)
  • TABLE 42 ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 43 STATE-WISE DISTRIBUTION OF CANCER IN INDIA
  • TABLE 44 ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017
  • TABLE 45 REST OF WORLD CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURES LIST
  • FIGURE 1 NUMBER OF PEOPLE LIVING WITH CANCER ACROSS THE GLOBE FOR PERIOD 2012-2020 (MILLION)
  • FIGURE 2 GLOBAL CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 3 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
  • FIGURE 4 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
  • FIGURE 5 LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA
  • FIGURE 6 GLOBAL CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
  • FIGURE 7 GLOBAL GENOMICS MARKET BY NEXT-GENERATION SEQUENCING (NGS) 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL GENOMICS MARKET BY MICROARRAY 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL GENOMICS MARKET BY POLYMERASE CHAIN REACTION (PCR) 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL PROTEOMICS MARKET BY MASS SPECTROMETRY 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL PROTEOMICS MARKET BY 2D GEL ELECTROPHORESIS 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL PROTEOMICS MARKET BY PROTEIN MICROARRAY TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL PROTEOMICS MARKET BY ANTIBODY ARRAY TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL PROTEOMICS MARKET BY PEPTIDE ARRAY TECHNOLOGY 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY METABOLOMICS 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY GLYCOMICS 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL IMAGING TECHNOLOGIES MARKET BY MAGNETIC RESONANCE IMAGING(MRI) 2019-2027 ($ MILLION)
  • FIGURE 18 GLOBAL IMAGING TECHNOLOGIES MARKET BY POSITRON EMISSION TOMOGRAPHY (PET) 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL IMAGING TECHNOLOGIES MARKET BY COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)
  • FIGURE 20 GLOBAL IMAGING TECHNOLOGIES MARKET BY MAMMOGRAPHY 2019-2027 ($ MILLION)
  • FIGURE 21 GLOBAL IMAGING TECHNOLOGIES MARKET BY ULTRASOUND 2019-2027 ($ MILLION)
  • FIGURE 22 GLOBAL IMMUNOASSAYS MARKET BY IMMUNOHISTOCHEMISTRY(IHC) TESTS 2019-2027 ($ MILLION)
  • FIGURE 23 GLOBAL IMMUNOASSAYS MARKET BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 2019-2027 ($ MILLION)
  • FIGURE 24 GLOBAL IMMUNOASSAYS MARKET BY FLOW CYTOMETRY 2019-2027 ($ MILLION)
  • FIGURE 25 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY IN SITU HYBRIDIZATION 2019-2027 ($ MILLION)
  • FIGURE 26 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY OTHERS CYTOGENETICS-BASED TESTS 2019-2027 ($ MILLION)
  • FIGURE 27 GLOBAL CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
  • FIGURE 28 GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
  • FIGURE 29 GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
  • FIGURE 30 PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 31 GLOBAL CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 32 THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)
  • FIGURE 34 CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 35 GERMANY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 36 THE UNITED KINGDOM CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 37 FRANCE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 38 ITALY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 39 SPAIN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 40 REST OF EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 41 CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 42 INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 43 JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 44 SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 45 AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 46 REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 47 LATIN AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 48 MIDDLE EAST AND AFRICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
  • FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)
Back to Top